Mechanistic research dossiers with linked tools for reconstitution, mg/kg ranges and half-life curves. For investigative and educational use only.
← Back to peptide library

Sermorelin

Synthetic growth hormone–releasing hormone (GHRH 1–29) analogue used to probe pituitary GH reserve and to model physiologic, pulsatile GH secretion.
Evidence: Strong Human + Preclinical Function: GH Axis & Diagnostics Class: GHRH receptor agonist
Explore calculators for this peptide
Use the Peptide Research Tools to experiment with Sermorelin reconstitution, mcg/kg exposure curves and GH stimulation test–style protocols. All values are placeholders and must be aligned with your own research protocol.
Open Sermorelin in calculators →
Research frame & potential applications
Sermorelin is a truncated analogue of endogenous GHRH that binds the GHRH receptor on pituitary somatotrophs to induce physiologic pulses of growth hormone. It has been used clinically as a diagnostic tool for GH deficiency and as a research agent to study GH pulsatility, IGF-1 dynamics and more “natural” GH-axis stimulation compared with exogenous GH.

Research areas & putative benefits

How Sermorelin is positioned in GH-axis and endocrine research.

  • Assessing pituitary GH reserve in children and adults with suspected GH deficiency.
  • Exploring physiologic GH and IGF-1 patterns using pulse-based stimulation rather than continuous exogenous GH.
  • Studying synergy with ghrelin receptor agonists (e.g. Ipamorelin) in dual-pathway GH research models.
  • Modelling age-related decline in GHRH signalling and potential restoration strategies.

Mechanism stack

Key mechanisms underlying Sermorelin’s GH-axis effects.

Primary target
GHRH receptor agonism
Sermorelin binds to GHRH receptors on pituitary somatotrophs, activating cAMP/PKA signalling to stimulate GH synthesis and release in a pattern similar to endogenous GHRH.
Pulse physiology
Pulsatile GH secretion
Because of its short half-life and receptor kinetics, Sermorelin generates GH spikes that preserve circadian rhythm and hypothalamic feedback loops rather than producing constant high GH levels.
Downstream effects
IGF-1 and metabolic signals
Repeated Sermorelin-driven GH pulses raise circulating IGF-1 and influence body composition, recovery and metabolic parameters in research settings, within the constraints of endogenous feedback.
Diagnostic use
GH-axis stimulation tests
Sermorelin has been used as a safer alternative to insulin-induced hypoglycaemia or arginine tests to evaluate GH deficiency by measuring GH and IGF-1 responses to controlled stimulation.

Risk frame & unknowns

Considerations around Sermorelin as a GH-axis tool.

Important research caveats
  • Chronic GH-axis stimulation can influence glucose tolerance, fluid balance and cardiovascular structure even with physiologic pulsatility.
  • Data on long-term Sermorelin use outside diagnostic protocols are more limited than its testing history.
  • Combination protocols with other GH or IGF-1–active agents can create complex feedback effects that are not fully mapped.
  • Use outside regulated, supervised research or clinical environments carries the usual risks of GH/IGF-axis overactivation.
This dossier summarizes mechanistic, preclinical and clinical findings on Sermorelin for scientific and educational purposes only. It does not provide medical advice, treatment guidance or dosing recommendations.